Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 2Lymphoma, Mantle-Cell 2Multiple Myeloma 1Melanoma 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1

Interventions

Rituximab 24Lenalidomide 12Cyclophosphamide 12fludarabine phosphate 10Peripheral Blood Stem Cell Transplantation 10Mycophenolic Acid 6Cyclosporine 6Whole-Body Irradiation 5Radiotherapy 5Filgrastim 5ibritumomab tiuxetan 4Indium 4Etoposide 4romidepsin 3Sirolimus 3Prednisone 3Pentostatin 3Methotrexate 3Melphalan 3In Situ Hybridization, Fluorescence 3Gene Expression Profiling 3Everolimus 3Busulfan 3Bortezomib 3Bendamustine Hydrochloride 3zanubrutinib 2venetoclax 2veltuzumab 2temsirolimus 2obinutuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, B-Cell, Marginal Zone × obatoclax × Clear all
NCT01238146 2013-06-06

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡